Stayble Therapeutics AB (OSTO:STABL) Research & Development : kr0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Stayble Therapeutics AB Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Stayble Therapeutics AB's Research & Development for the three months ended in Sep. 2023 was kr0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 was kr0.00 Mil.

Stayble Therapeutics AB Research & Development Historical Data

The historical data trend for Stayble Therapeutics AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB Research & Development Chart

Stayble Therapeutics AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Research & Development

Get a 7-Day Free Trial

Stayble Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Research & Development	Get a 7-Day Free Trial															-	-	-	-	-

Stayble Therapeutics AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

Stayble Therapeutics AB (OSTO:STABL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Stayble Therapeutics AB Research & Development Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Stayble Therapeutics AB (OSTO:STABL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (OSTO:STABL) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

4K4:Germany

Address

Medicinaregatan 8a, Gothenburg, SWE, SE-413 90

Website

http://www.staybletherapeutics.com

Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (OSTO:STABL) Headlines

No Headlines